Madrigal Pharms

MDGL NASDAQ
95.24
+0.32
+0.34%
After Hours: 95.24 0 0.00% 16:53 07/18 EDT
Open
94.58
Prev Close
94.92
High
95.24
Low
92.67
Volume
134.23K
Avg Vol (3M)
158.15K
52 Week High
292.29
52 Week Low
89.83
% Turnover
0.87%
Market Cap
1.47B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Madrigal Pharms MDGL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
MORE >

Recently

Name
Price
%Change